Graf Acquisition Corp. IV (GFOR) Adds $10M in Note Funding to NKGen Biotech Deal
by Nicholas Alan Clayton on 2023-09-18 at 10:15am

Graf Acquisition Corp. IV (NYSE:GFOR) announced in an 8-K this morning that it has added $10 million in convertible note funding to its combination with NKGen Biotech.

NKGen’s majority shareholder NKMax (KOSDAQ:182400) has put up the cash for the move and in exchange the notes are to bear interest payable at either a 5% rate in cash or 8% in stock. They will mature in 2027 on the agreement’s fourth anniversary and can be exercised for 1,000,000 shares at $11.50 per share.

This new funding comes as Graf IV has postponed its completion vote with NKGen three times as it engages with shareholders and tries to hit its $50 million minimum cash condition.

Its shareholders are currently set to reconvene at 10 am ET, September 20 and it has until September 25 to complete a deal.

Graf IV went into this string of meetings with about $62.2 million in trust and NKMax had already committed to a backstop of up to $25 million. According to the filing, the SPAC plans to continue to seek out additional funds to bring the deal to a close.

The $160 million combination was initially announced in April of this year. Santa Ana, California-based NKGen has five pharmaceutical formulas that have each reached some stage of Phase I and Phase II clinical trials seeking potential therapies for cancer and neurodegenerative conditions like Parkinson’s and Alzheimer’s.

Recent Posts
by Nicholas Alan Clayton on 2024-06-10 at 8:08pm

Centurion Acquisition Corp announced the pricing of its $250 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ALFUU”, Tuesday, June 11, 2024. The new SPAC aims to combine with a technology company with a focus on video gaming, interactive entertainment and enabling services and technologies, cybersecurity, artificial...

by Nicholas Alan Clayton on 2024-06-10 at 3:36pm

Rising Dragon Acquisition Corp (NASDAQ:RDACU) has filed for a $50 million SPAC to hunt for a small cap target in cutting age technology. The SPAC’s units are to be funded to 100% at $10 per unit while including no warrants. Each unit would have a 1/10 right, however, which has been overall not an uncommon...

by Nicholas Alan Clayton on 2024-06-10 at 11:48am

Bayview (NASDAQ:BAYA) has entered into a definitive agreement to combine with Chinese fintech Oabay at an enterprise value of $393 million. Oabay provides cloud-based software to help companies optimize their supply chains with trade credit solutions. The combined company is expected to trade on the Nasdaq once the deal is completed in late 2024. Transaction...

by Nicholas Alan Clayton on 2024-06-10 at 8:25am

At the SPAC of Dawn Last week ended with a flurry of SPAC activity, which may continue into the middle of the month although there are fewer planned corporate actions on the docket for the week. Friday saw three new SPACs file for IPOs bringing June’s tally to four so far. This continues the strong...

by Kristi Marvin on 2024-06-08 at 9:52am

Terms Tracker for the Week Ending June 7, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. As expected, June is looking like a much more active month for SPACs, particularly on the new issuance front. Four more new SPACs got filed...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved